News about Clinical Trials

Suven Completes Phase 3 Enrollment of Masupirdine for Alzheimer's-Related Agitation

Suven Life Sciences completes enrollment in its global Phase 3 masupirdine trial, with 424 patients randomised to evaluate the therapy for agitation associated with Alzheimer’s dementia.

Clinical Trials | 05/09/2026 | By News Bureau

Tangram Therapeutics Advances TGM-312 into MASH Patient Cohorts in Phase 1/2 Trial

Tangram Therapeutics advances TGM-312 into MASH patient cohorts in its Phase 1/2 RESTORE-MASH trial while appointing Dr Sonya Montgomery as Chief Development Officer to drive its clinical pipeline.

Clinical Trials | 05/09/2026 | By News Bureau

Novartis Reports Phase 3 Results for Pelacarsen in Cardiovascular Disease

Novartis reports phase 3 Lp(a)HORIZON topline results for pelacarsen, an investigational ASO targeting Lp(a) production in patients with cardiovascular disease (CVD).

Clinical Trials | 05/09/2026 | By News Bureau

Ultragenyx Announces Phase 3 Aspire Results in Angelman Syndrome

Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI).

Clinical Trials | 04/09/2026 | By News Bureau

Teva Pharmaceuticals Reports Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease

Teva Pharmaceuticals reports positive phase 2a results for TEV ‘408, an anti-IL-15 antibody that significantly prevented gluten-induced intestinal damage in celiac disease.

Clinical Trials | 03/09/2026 | By News Bureau

Novartis Remibrutinib Reduces Relapse Rates in Phase 3 RMS Trials

Novartis’ remibrutinib significantly reduces annualised relapse rates versus teriflunomide in phase 3 RMS trials, with a favorable safety profile and no liver safety signal.

Clinical Trials | 02/09/2026 | By News Bureau

GSK to Advance mRNA Seasonal Flu Vaccine Candidate to Phase 3

GSK advances its mRNA seasonal flu vaccine to phase 3 after positive phase 2 data showed higher immune responses versus standard and high-dose vaccines.

Clinical Trials | 02/09/2026 | By News Bureau

Daiichi Sankyo Begins Clinical Development of CD25-Targeted ADC DS1025

Daiichi Sankyo advances DS1025 into clinical development as a potential first-in-class CD25-targeted Antibody Drug Conjugate (ADC) for patients with advanced solid tumors.

Clinical Trials | 01/09/2026 | By News Bureau

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110 HER2 ADC Biosimilar

Formosa Pharmaceuticals files a clinical trial application for TSY-110, a HER2-targeting Antibody Drug Conjugate (ADC) biosimilar positioned as a potential alternative to Roche’s Kadcyla.

Clinical Trials | 01/09/2026 | By News Bureau

Ireland Establishes Clinical Trials Advisory Council to Accelerate Clinical Research Reforms

Ireland’s new Clinical Trials Advisory Council held its inaugural meeting on August 27, 2026, beginning work on reforms aimed at improving clinical research, patient access and life sciences investment.

Clinical Trials | 31/08/2026 | By News Bureau